TD Asset Management Inc Trims Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

TD Asset Management Inc trimmed its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGEFree Report) by 33.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 53,662 shares of the biopharmaceutical company’s stock after selling 27,000 shares during the quarter. TD Asset Management Inc owned approximately 0.09% of Sage Therapeutics worth $1,163,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its stake in Sage Therapeutics by 353.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,937 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 5,406 shares during the period. Quest Partners LLC purchased a new position in shares of Sage Therapeutics during the fourth quarter worth about $261,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Sage Therapeutics by 31.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,256 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 2,967 shares during the last quarter. Handelsbanken Fonder AB increased its position in Sage Therapeutics by 29.8% in the 4th quarter. Handelsbanken Fonder AB now owns 12,644 shares of the biopharmaceutical company’s stock valued at $274,000 after acquiring an additional 2,900 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new stake in Sage Therapeutics during the 4th quarter valued at approximately $293,000. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Price Performance

Shares of NASDAQ SAGE opened at $10.58 on Monday. The firm’s 50-day moving average is $13.29 and its two-hundred day moving average is $19.18. The company has a market capitalization of $636.70 million, a PE ratio of -1.26 and a beta of 0.91. Sage Therapeutics, Inc. has a 12-month low of $10.44 and a 12-month high of $59.99.

Sage Therapeutics (NASDAQ:SAGEGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.17). The company had revenue of $7.90 million for the quarter, compared to analyst estimates of $5.26 million. Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. The company’s revenue for the quarter was up 139.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.46) earnings per share. On average, analysts forecast that Sage Therapeutics, Inc. will post -6.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SAGE. Wedbush reissued a “neutral” rating and issued a $24.00 target price on shares of Sage Therapeutics in a report on Wednesday, April 17th. TD Cowen cut their price objective on shares of Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, April 18th. Canaccord Genuity Group lowered their target price on shares of Sage Therapeutics from $21.00 to $17.00 and set a “hold” rating on the stock in a report on Friday, April 26th. HC Wainwright cut their price target on shares of Sage Therapeutics from $28.00 to $25.00 and set a “neutral” rating for the company in a report on Friday, April 26th. Finally, Oppenheimer lowered their price objective on Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating on the stock in a report on Thursday, April 18th. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $35.05.

Read Our Latest Report on SAGE

Sage Therapeutics Company Profile

(Free Report)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

Featured Stories

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.